How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
about
Malignant gliomas: old and new systemic treatment approachesRecurrent Glioblastoma: Where we standNonsurgical treatment of recurrent glioblastomaBevacizumab: a treatment option for recurrent glioblastoma multiforme.Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).Cisplatinum and BCNU chemotherapy in primary glioblastoma patients.Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.Bevacizumab and daily temozolomide for recurrent glioblastoma.Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.Impact of imaging measurements on response assessment in glioblastoma clinical trialsBevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.Canadian recommendations for the treatment of glioblastoma multiforme.Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.CNS Anticancer Drug Discovery and Development Conference White Paper.Standards of care for treatment of recurrent glioblastoma--are we there yet?Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.Experience with irinotecan for the treatment of malignant gliomaHypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience.Advances in the treatment of malignant gliomas.End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Treating recurrent glioblastoma: an update.Nitrosoureas in the Management of Malignant Gliomas.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Bevacizumab in recurrent glioblastoma: open issues.AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.Recurrent high-grade glioma.ACNU-based chemotherapy for recurrent glioma in the temozolomide era.Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.Bevacizumab in brain tumors: ready for primetime?
P2860
Q26744387-E6BFD2E5-2439-4669-8DC7-C33E03AFA2B9Q26765042-9A743601-86CE-4DDC-9663-96DF23BE033EQ26795560-600711EB-88F8-447A-B83E-759DD656226DQ33365902-2FFD5D26-1BF1-4CE1-BC22-79AC4046EF2DQ33382912-0BBE72B2-49B3-4163-ACBF-116113418A25Q33383259-2169B785-2699-4F54-B45E-F6658E5297DBQ33392078-39401BAB-26A6-415B-B151-DB4EC9FF3AE1Q33396384-8DA03C54-8E6A-4734-B35C-110539D47577Q33402044-8A3BFC61-46B6-4CE7-8BFD-FD5AB6954B73Q33407127-8EF8B22F-BC3C-4F61-A862-7572CE39915AQ33528294-934F86F7-FF59-4AE0-9FF8-A7916C36150DQ34331328-9BC6A19A-2978-4D58-889F-18A84C3201EBQ35184830-C9D709BF-8429-4DB6-8C0B-461B0447E480Q35676452-3827BCF8-8327-424D-BA46-5A8D373F003AQ35733207-57AEFD1B-05B3-46B1-ABC4-7C53E88CF82CQ35855352-19082080-69F1-4422-A0B5-EE2F179251A2Q35920319-CBC563BD-4EBD-477C-AA7B-654FB1C10D81Q36089590-99A58763-D9A3-4FCF-A707-94E0F570664BQ36500401-06DF1286-65AD-4D0B-A620-F356786156B9Q36949475-BE6BA7E5-182E-4901-AB40-D4D7B633A0F5Q37265907-7754C01B-4137-4228-B655-561E44CE5F6CQ37366417-B0BD97C8-0CAE-44E8-9967-C33C4CF41300Q37738770-B9C5CF17-BF5A-48BE-B2CA-B1E9C7B627C4Q37952239-C0641B1D-C772-4F44-ADCC-AE8244A92971Q38093776-6536781B-285E-421E-9CC1-75FF5A56E5C4Q38179019-120BD1F5-D7DC-43C9-8FE8-A27E773F3E4BQ38205133-41605014-41A3-4828-A2BF-B568BD7CE5F4Q38376610-99EA6BFF-8BDC-483F-87E5-8674F63F0272Q38691732-83F09F4F-92C4-404D-8A91-FB27DD03DC56Q38720644-F2C3113E-7D4E-46A3-87DB-421BEFAFB9A1Q38965301-7CCF4C35-CD1E-45D3-AA6E-AE0F1576F025Q41139015-15E3EA07-6A31-4BBB-86B6-C52A4AD64FB7Q41250426-C151FFBD-59D9-4FD8-B984-B02DB114AAA1Q41403487-C2C0601C-9D1D-4300-A7EB-1655DEB5A4BDQ42906999-7AEC7EC0-90CA-4353-A4BA-42189C33FE6DQ46261735-62E73DC2-7D6E-458C-BD8F-821943674052Q48125310-95B90EC2-C7C1-4932-B594-EA349FE1A3A0Q48132543-5D686072-58B8-4FC9-94A0-CDC68244AC22Q48399854-E2D624C8-1E90-4364-AEDE-6EDAA630706AQ48425942-9FC4A3E0-0F41-4AC1-B118-79E200208569
P2860
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@en
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@nl
type
label
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@en
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@nl
prefLabel
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@en
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@nl
P2093
P1433
P1476
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
@en
P2093
A A Brandes
L Nicolardi
P304
P356
10.1212/01.WNL.0000140495.33615.CA
P407
P577
2004-10-01T00:00:00Z